MedTrace Logo

The Effect of Bezafibrate on Cholestatic Itch

NCT02701166 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2016-03-08

No results posted yet for this study

Summary

Randomized double blind placebo controlled trial to evaluate the antipruritic effect of bezafibrate in patients with moderate to severe cholestatic itch.

Conditions

Interventions

DRUG

Bezafibrate

bezafibrate 400mg per day

DRUG

Placebo

placebo 400mg per day

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Leiden University Medical Center

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • Radboud University Medical Center

    collaborator OTHER

  • Maastricht University Medical Center

    collaborator OTHER

  • Free University Medical Center

    collaborator OTHER

  • University of Barcelona

    collaborator OTHER

  • Ludwig-Maximilians - University of Munich

    collaborator OTHER

  • Friedrich-Alexander-Universität Erlangen-Nürnberg

    collaborator OTHER

  • Istituto Clinico Humanitas

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-02-28
Completion
2018-04-30

Countries

  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02701166 on ClinicalTrials.gov